Stoke Therapeutics logo

Stoke TherapeuticsNASDAQ: STOK

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 June 2019

Next earnings report:

25 March 2025

Last dividends:

N/A

Next dividends:

N/A
$599.06 M
-47%vs. 3y high
69%vs. sector
-vs. 3y high
-vs. sector
-60%vs. 3y high
64%vs. sector
-88%vs. 3y high
91%vs. sector

Price

after hours | Wed, 20 Nov 2024 21:25:34 GMT
$11.31-$0.30(-2.58%)

Dividend

No data over the past 3 years
$4.89 M$4.10 M
$4.89 M-$26.43 M

Analysts recommendations

Institutional Ownership

STOK Latest News

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
zacks.com05 November 2024 Sentiment: POSITIVE

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.55 per share a year ago.

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
seekingalpha.com07 September 2024 Sentiment: POSITIVE

STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026.

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
zacks.com07 August 2024 Sentiment: POSITIVE

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.69 per share a year ago.

Stoke Therapeutics to Present at Upcoming Investor Conferences in June
businesswire.com03 June 2024 Sentiment: POSITIVE

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldman Sachs 45th Annual Global Healthcare Conference Date: Monday, June 10, 2024 Time: 4:00 p.m. ET TD Cowen Genetic Medicines & RNA Summit Date: Thursday, June 20, 2024 Time: 1.

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research06 May 2024 Sentiment: POSITIVE

Stoke Therapeutics, Inc. (STOK) reported a quarterly loss of $0.57 per share, slightly better than the expected loss of $0.60 per share according to the Zacks Consensus Estimate. This is compared to a loss of $0.53 per share in the same quarter last year.

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Zacks Investment Research27 March 2024 Sentiment: POSITIVE

Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research25 March 2024 Sentiment: POSITIVE

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.

Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
Zacks Investment Research29 February 2024 Sentiment: POSITIVE

Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
Zacks Investment Research26 February 2024 Sentiment: POSITIVE

Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?
Zacks Investment Research15 February 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What type of business is Stoke Therapeutics?

Stoke Therapeutics, Inc., a early-stage biopharmaceutical company, is developing new antisense oligonucleotide drugs for the treatment of underlying causes of severe genetic diseases. Its lead drug candidate, STK-001, is being used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to conduct genetic testing. Previously known as ASOthera Pharmaceuticals, Inc., the company changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

What sector is Stoke Therapeutics in?

Stoke Therapeutics is in the Healthcare sector

What industry is Stoke Therapeutics in?

Stoke Therapeutics is in the Biotechnology industry

What country is Stoke Therapeutics from?

Stoke Therapeutics is headquartered in United States

When did Stoke Therapeutics go public?

Stoke Therapeutics initial public offering (IPO) was on 19 June 2019

What is Stoke Therapeutics website?

https://www.stoketherapeutics.com

Is Stoke Therapeutics in the S&P 500?

No, Stoke Therapeutics is not included in the S&P 500 index

Is Stoke Therapeutics in the NASDAQ 100?

No, Stoke Therapeutics is not included in the NASDAQ 100 index

Is Stoke Therapeutics in the Dow Jones?

No, Stoke Therapeutics is not included in the Dow Jones index

When was Stoke Therapeutics the previous earnings report?

No data

When does Stoke Therapeutics earnings report?

The next expected earnings date for Stoke Therapeutics is 25 March 2025